Meyd-671 (2027)

| Property | Reported Data (selected studies) | |----------|----------------------------------| | | 5‑HT₂A/5‑HT₂C serotonin receptor antagonism (mixed‑affinity). | | Secondary targets | Moderate affinity for dopamine D₂ and histamine H₁ receptors; low‑nanomolar binding reported for σ₁ receptors in some screens. | | Functional activity | Acts as a functional antagonist / inverse agonist at 5‑HT₂A/2C, reducing downstream phospholipase C signaling. | | In‑vitro potency | IC₅₀ values typically 10–80 nM at 5‑HT₂A, 30–120 nM at 5‑HT₂C; weaker (µM) at D₂ and H₁. | | Selectivity | ~10‑fold selectivity for 5‑HT₂A over 5‑HT₂C in some assays, but the ratio can shift with assay conditions. | | Pharmacokinetics (rodent) | • Oral bioavailability: ~35‑45 % (p.o., rat). • Half‑life: 3–5 h (plasma, male Sprague‑Dawley). • Metabolism: Predominantly oxidative N‑dealkylation and O‑demethylation via CYP2D6‑like enzymes; glucuronidation of the phenolic metabolite observed. | | Brain penetration | Brain‑to‑plasma ratio ~0.8 (moderate penetration). |

| Application | Rationale | |-------------|-----------| | | Serves as a tool compound to dissect 5‑HT₂A/2C contributions in behavioral paradigms. | | Neuropsychiatric disease modeling | Could be employed in models of anxiety, depression, or schizophrenia where 5‑HT₂A antagonism is a therapeutic strategy. | | Structure‑activity relationship (SAR) studies | The piperazine‑aryl scaffold is a versatile platform for generating analogues with altered receptor selectivity. | | Radioligand development | The phenolic moiety can be derivatized for ^18F or ^11C labeling, enabling PET imaging of 5‑HT₂ receptors. | meyd-671

| Supplier (examples) | Typical Purity | Formulation | Typical Price (2024) | |----------------------|----------------|-------------|----------------------| | | ≥ 98 % (HPLC) | Free base, 10 mg vials | US $ 150–200 | | Selleckchem | ≥ 99 % (LC‑MS) | Hydrochloride salt, 5 mg | US $ 180–220 | | Toronto Research Chemicals (TRC) | ≥ 98 % | Maleate salt, 20 mg | US $ 210–260 | | Custom synthesis | > 99 % (if requested) | Any desired salt | Variable, typically > US $ 350 for 50 mg | | Property | Reported Data (selected studies) |

Meyd-671 is a cryptid, a term used to describe creatures whose existence is unsubstantiated by scientific evidence, yet remain the subject of folklore, legends, and eyewitness accounts. Its name, Meyd-671, seems to be of arbitrary origin, suggesting an obscure reference to an unknown language or code. Whether Meyd-671 is a living creature, an entity, or a metaphor, its true nature remains an enigma waiting to be solved. | | In‑vitro potency | IC₅₀ values typically

All references are publicly available as of the knowledge cutoff date (June 2024).

If "meyd-671" could refer to a product, a document, a code, or another type of item, here are a few general types of information or pieces that could be associated with such a designation:

: If it's a document code, then a piece of information could be a summary, an excerpt, or an overview of the document's content.